Sign up Australia
Proactive Investors - Run By Investors For Investors

Invion teams with Hudson Institute to advance light-based cancer therapy research

Initial projects will focus on ovarian cancer and will expand into other cancer indications.
cancer cells
Light-based therapy to kill cancer cells

Invion Ltd (ASX:IVX) has signed a research and development (R&D) agreement with leading Australian medical research institute, Hudson Institute of Medical Research.

The agreement provides a framework for Invion and Hudson Institute to collaborate on R&D projects based on Invion’s Photosoft technology for the treatment of cancers.

Light-based therapy to kill cancer cells

Invion is developing Photosoft as a next generation photo dynamic therapy (PDT).

PDT uses non-toxic photosensitisers and visible light in combination with oxygen to kill malignant cells, shut down tumours and to stimulate the immune system.

In contrast to surgery, radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation and invasion of a tumour by leukocytes.

Targeting circulating cancer cells and deeply seated tumours

Photosoft is targeted to address the limitations of first-generation PDT therapies through better solubility and stronger absorption that allows deeper penetration of tissues and better tumour specificity.

Invion’s Photosoft uses a laser light activation method based on short, pulsating ‘near infrared’ (NIR) wavelengths.

It is hypothesised that NIR light therapy allows more effective whole-of-body systemic treatment that can target circulating cancer cells as well as deeply seated tumours.

Initial projects to focus on ovarian cancer

Under the new agreement, Hudson Institute will provide the research facilities and expertise required to undertake individual Invion-sponsored research projects.

Furthermore, Hudson Institute will be responsible for all legislative and professional standards compliance requirements, in accordance with global best practice.

Initial projects will focus on ovarian cancer, and it is envisioned that projects will quickly expand into other cancer indications.

READ: Invion's strategic alliance with Cho Group provides distribution opportunities

Invion has an agreement with The Cho Group to conduct clinical development of Photosoft globally.

The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset.

View full IVX profile View Profile

Invion Ltd Timeline

September 01 2015
August 28 2015
March 12 2015

Related Articles

January 19 2018
Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex
cancer cell
February 01 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use